埃托里可西布诱导的固定红斑
Corina Porr1, Dana M Harris2, Anca Vidrighin3
1Allergology Department, Faculty of Medicine, Lucian Blaga University, 550169 Sibiu, Romania.
Journal of clinical medicine
|December 11, 2025
概括
固定药物喷发 (FDE) 是一种T细胞介导的反应. 这一案例突显了埃托里科西布作为触发剂,以及诊断测试对于识别FDE管理的安全替代品的重要性.
科学领域:
- 皮肤病学 皮肤病学
- 临床免疫学临床免疫学
背景情况:
- 固定药物喷发 (FDE) 是一种CD8+T细胞介导的过敏症.
- 在药物再暴露后,在同一部位出现重复的斑块的特征.
- 常见的触发因素包括NSAID和抗生素;像HLA等位基因因素发挥作用.
研究的目的:
- 为了确定固定药物喷发 (FDE) 的致病原体.
- 通过诊断测试来确认延迟型过敏症.
- 评估FDE潜在的安全治疗替代方案.
主要方法:
- 临床评估包括贴片测试和口服药物诱导.
- 评估用于FDE管理的替代药物.
- 详细的病史和体检. 详细的病史和体检.
主要成果:
- 一名53岁的妇女在服用埃托里可西布后出现FDE.
- 口服挑战证实埃托里科西布是FDE触发物;补丁测试是负面的.
- 切莱科克西布被确定为一种潜在的安全替代治疗方法.
结论:
- 延迟皮肤药物反应的准确诊断需要采用综合方法.
- 临床评估和确认性测试对于FDE诊断至关重要.
- 确定安全的治疗选择对于患者管理至关重要.
相关概念视频
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.3K
Dosage Regimen: Fixed Dose
2.3K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.3K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.0K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.0K
Allergic Drug Reactions
1.3K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.3K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
436
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
436
Endocarditis II: Clinical Features of Infective Endocarditis
371
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
371


